TIMOTHY ANDREW MCCARTHY M.D. NPI 1881963403

NPI Details

Timothy Andrew Mccarthy, M.D. is a hematology and oncology internal medicine in Fairfax, VA with 17 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Timothy Andrew Mccarthy, M.D. NPI is 1881963403. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: RUTGERS, ROBERT WOOOD JOHNSON MEDICAL SCHOOL
Graduation Year:2009

The provider's business location address is:

8613 LEE HWY # 200N
FAIRFAX, VA
ZIP 22031-171
Phone: (703) 208-3155
Fax: (703) 280-9596

The NPI 1881963403 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, pemetrexed, not otherwise specified, 10 mg (HCPCS:J9305)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Nephelometry, test method using light (HCPCS:83883)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Protein measurement, serum (HCPCS:84165)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Unclassified drugs (HCPCS:J3490)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Haptoglobin (serum protein) level (HCPCS:83010)
• Folic acid level, serum (HCPCS:82746)
• Uric acid level, blood (HCPCS:84550)
• Red blood count automated, with additional calculations (HCPCS:85046)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Magnesium level (HCPCS:83735)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Red blood cell sedimentation rate, to detect inflammation, non-automated (HCPCS:85651)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Refilling and maintenance of portable pump (HCPCS:96521)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Injection of drug or substance into vein (HCPCS:96374)
• Total protein level, blood (HCPCS:84155)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)

The enumeration date for this NPI number is 12/28/2011 and was last updated on 11/10/2025.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.